SOPHiA GENETICS partners with AstraZeneca on two oncology companion diagnostics

SOPHiA GENETICS entered a multi-year global collaboration with AstraZeneca to develop, validate, deploy two companion diagnostics for precision oncology therapies.

Deal targets decentralized companion diagnostics, aiming to support AstraZeneca launches across laboratories regardless of geography.

Solid Tumor application to be developed into a decentralized companion diagnostic; Hematological Oncology application to be developed, validated for blood cancer.

SOPHiA GENETICS and AstraZeneca expand oncology diagnostics collaboration

Related News

UL Solutions Q2 revenue rises 5.2%, slightly beats estimates

Camp4 Therapeutics closes second tranche of private placement, raises $50.1 million

Energizer Q3 sales beat estimates on global distribution gains

Strata Critical Q2 adjusted EBITDA rises to $7.9 million; revenue increases 7% year-on-year to $72.5 million

McDonald's US sales disappoint as value deals fail to draw enough diners